SRx Health (SRXH) CEO reports new equity, warrant and preferred awards

Rhea-AI Filing Summary

SRx Health Solutions, Inc. Chief Executive Officer Kent Douglas Cunningham reported multiple equity awards that increase his ownership exposure, with no sales disclosed. On March 16, 2026, he received 247,522 Series B Warrants with an exercise price of $0.3182 per share, exercisable into the same number of common shares and expiring on March 16, 2029. On the same date he was also granted 63 shares of Series B Preferred Stock at $800 per share. Earlier awards include common stock grants of 231,193 shares on August 25, 2025 and 200,000 shares on December 3, 2025, both recorded as grants/awards rather than open-market purchases. One 44,464-share common stock position is held indirectly through Halo Spin-Out SPV Inc. The filing also reports a prior grant of 8,000 stock options with a $5.00 exercise price and 8,000 underlying common shares, along with several smaller common stock awards, all categorized as compensation-related acquisitions.

Insider Trade Summary

9 transactions reported

Mixed 9 txns

Insider Cunningham Kent Douglas

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Series B Warrants	247,522	$0.3182	$79K
Grant/Award	Series B Preferred Stock	63	$800.00	$50K
Grant/Award	Common Stock	200,000	$0.39	$78K
Grant/Award	Common Stock	44,464	$0.33	$15K
Grant/Award	Common Stock	231,193	$0.404	$93K
Grant/Award	Common Stock	84,906	$1.59	$135K
Grant/Award	Common Stock	71,770	$2.09	$150K
Grant/Award	Stock Options - Right to Buy	8,000	$5.00	$40K
Grant/Award	Common Stock	22,727	$4.17	$95K

Holdings After Transaction: Series B Warrants — 247,522 shares (Direct); Series B Preferred Stock — 63 shares (Direct); Common Stock — 655,060 shares (Direct); Common Stock — 455,060 shares (Indirect, Indirectly owned through ownership in Halo Spin-Out SPV Inc.); Stock Options - Right to Buy — 8,000 shares (Direct)

Footnotes (1)

Key Figures

Series B Warrants granted: 247,522 warrants at $0.3182 Series B Preferred Stock granted: 63 shares at $800 Common stock award: 231,193 shares at $0.4040 +5 more

8 metrics

Series B Warrants granted 247,522 warrants at $0.3182 Grant on March 16, 2026; exercisable into 247,522 common shares

Series B Preferred Stock granted 63 shares at $800 Preferred stock grant on March 16, 2026

Common stock award 231,193 shares at $0.4040 Grant on August 25, 2025; compensation-related acquisition

Common stock award 200,000 shares at $0.3900 Grant on December 3, 2025; total direct common shares then 655,060

Indirect common shares 44,464 shares at $0.3300 Held indirectly via Halo Spin-Out SPV Inc. from September 26, 2025 grant

Stock options granted 8,000 options at $5.00 Grant on June 26, 2024; underlying 8,000 common shares; expire June 26, 2034

Common stock grant 84,906 shares at $1.59 Grant on April 25, 2025; total direct common shares then 179,403

Initial reported common stock grant 22,727 shares at $4.17 Grant on June 26, 2024; first common stock award in this series

Key Terms

Series B Warrants, Series B Preferred Stock, Stock Options - Right to Buy, grant/award acquisition, +1 more

5 terms

Series B Warrants financial

"security_title: "Series B Warrants" with 247,522 underlying common shares"

Series B warrants are contracts issued alongside a company's Series B financing that give the holder the right to buy a set number of shares at a fixed price within a specified time. For investors, they matter because they can provide leveraged upside if the company grows, or they can dilute existing shareholders when exercised—like a coupon promising a future share at a known price that can add value or change ownership stakes.

Series B Preferred Stock financial

"security_title: "Series B Preferred Stock" with 63.0000 shares at $800.0000"

Series B preferred stock is a type of ownership share issued by a company that offers certain advantages over common stock, such as priority in receiving dividends or assets if the company is sold or liquidated. It is typically issued after an initial round of funding, making it a way for investors to support a company's growth while gaining some protections and benefits. This stock matters to investors because it often provides a more secure investment position with potential for future growth.

Stock Options - Right to Buy financial

"security_title: "Stock Options - Right to Buy" for 8,000.0000 shares at $5.0000"

grant/award acquisition financial

"transaction_action: "grant/award acquisition" for all A-coded transactions"

indirectly owned financial

"nature_of_ownership: "Indirectly owned through ownership in Halo Spin-Out SPV Inc.""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cunningham Kent Douglas

(Last) (First) (Middle)

801 US HIGHWAY 1

(Street)

NORTH PALM BEACH FLORIDA 33408

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SRx Health Solutions, Inc. [ SRXH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2024

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/03/2025		A		200,000	A	$0.39	655,060	D
Common Stock	09/26/2025		A		44,464	A	$0.33	455,060	I	Indirectly owned through ownership in Halo Spin-Out SPV Inc.
Common Stock	08/25/2025		A		231,193	A	$0.404	410,596	D
Common Stock	04/25/2025		A		84,906	A	$1.59	179,403	D
Common Stock	04/24/2025		A		71,770	A	$2.09	94,497	D
Common Stock	06/26/2024		A		22,727	A	$4.17	22,727	D
Series B Preferred Stock	03/16/2026		A		63	A	$800	63	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options - Right to Buy	$5	06/26/2024		A		8,000		06/26/2025	06/26/2034	Common stock	8,000	$5	8,000	D
Series B Warrants	$0.3182	03/16/2026		A		247,522		03/16/2026	03/16/2029	Common Stock	247,522	$0.3182	247,522	D

Explanation of Responses:

	/s/ Carolina Martinez, Attorney-in- fact	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did SRXH CEO Kent Douglas Cunningham report?

Kent Douglas Cunningham reported several equity awards, all classified as acquisitions, not open-market trades. These include grants of Series B Warrants, Series B Preferred Stock, common stock, and stock options, reflecting compensation-related increases in his exposure to SRx Health Solutions, Inc. shares over multiple dates.

How many Series B Warrants were granted to the SRXH CEO and at what price?

Cunningham received 247,522 Series B Warrants on March 16, 2026, each with an exercise price of $0.3182. These warrants are exercisable into 247,522 shares of common stock and expire on March 16, 2029, giving him additional leveraged exposure to future common share value.

What preferred stock awards did SRXH grant to its CEO in this filing?

On March 16, 2026, Cunningham was granted 63 shares of Series B Preferred Stock at $800 per share. This award is categorized as a grant or award acquisition, indicating it was part of compensation rather than an open-market purchase, and adds a preferred equity layer to his holdings.

Did the SRXH Form 4 show any insider sales by the CEO?

The Form 4 shows no sales; all reported transactions are coded as acquisitions (A) and described as grants or awards. These include common stock, preferred stock, warrants, and options, indicating compensation-related awards rather than disposals of existing holdings in SRx Health Solutions, Inc.

How many SRXH common shares were awarded to the CEO in 2025 grants?

In 2025, Cunningham received several common stock awards, including 231,193 shares on August 25, 200,000 shares on December 3, 84,906 shares on April 25, and 71,770 shares on April 24. All were recorded as grant or award acquisitions, expanding his common stock position through compensation.

What stock options related to SRXH common stock did the CEO receive?

On June 26, 2024, Cunningham was granted stock options covering 8,000 shares of common stock with a $5.00 exercise price. The options are a derivative award, with 8,000 underlying shares and an expiration date of June 26, 2034, providing long-dated participation in potential share appreciation.

Does the SRXH CEO hold any common stock indirectly?

Yes. The filing shows an award of 44,464 common shares on September 26, 2025 held indirectly through Halo Spin-Out SPV Inc. The nature of ownership is described as indirectly owned through that entity, distinguishing it from Cunningham’s directly held SRx Health Solutions, Inc. shares.